INVESTOR RELATIONS
(TSXV:VPT, OTC:VPTDF)
Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools. It sells its products worldwide.
CAPITAL STRUCTURE
Symbol: TSX-V: VPT & OTC: VPTDF
Shares Outstanding 133M
Shares Fully Diluted 148M
Recent Share Price CDN$.45 (US$.35)
52-Week Range CDN$.07-.60
Market Cap ca. CDN$60M (USD$46M)
Insider Ownership (FD) 6%
Public Float Ownership 94%
Debt None
Cash 2 years
Liquidity CDN$1.5M/day
USD$1.0M/day
OUR STRATEGY
Staying true to our story, Ventripoint Diagnostics Ltd. continues to be dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians, and most importantly improves the clinical experience for our youngest to oldest patient.
KEY AND STRATEGIC GOALS
2020
Read full report
Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.
VMS+ could eventually help treat our most loyal best friend.
EXPLORING NEW FRONTIERS FOR VMS+
Read More
LATEST FINANCIAL DATA
Quarterly Reports
Annual Reports
LATEST PRESS RELEASES
April 20, 2021
Ventripoint Attends 23rd Annual Canadian Echo Weekend and Grants Stock Options
April 19, 2021
Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing
of Heart Motion Tracking Technology
Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices
April 27, 2021
LATEST EVENTS
FEB
11
Ventripoint CEO interviewed on TraderTV Live
Ventripoint CEO interviewed by Torrey Hills Capital
FEB
04
LATEST EVENTS
FEB
11
Ventripoint CEO interviewed on TraderTV Live
Ventripoint CEO interviewed by Torrey Hills Capital
FEB
04
LATEST EVENTS
MAR
25
FEB
11
Ventripoint CEO interviewed on TraderTV Live
Ventripoint CEO interviewed by Torrey Hills Capital
FEB
04
LATEST EVENTS
APR
25
Ventripoint Diagnostics Update
MAR
25
Ventripoint CEO interview on BioPub
INVESTOR RELATIONS TEAM
Clay Chase
Torrey Hills Investor Relations
(858) 456-7300
Jonathan Robinson
Oak Hill Financial Inc.
(416) 669-1001
Adrian Sydenham
MarketSmart Communications Inc.
(877) 261-4466